Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB

Mov Disord. 2008 Sep 15;23(12):1776-80. doi: 10.1002/mds.22212.


This study investigated whether abnormalities in serotonin transporter binding occur in Parkinson's disease (PD) patients with concurrent depression. We estimated serotonin transporter levels in seven clinically depressed early-stage PD patients and in seven healthy matched-control subjects during a single positron emission tomography (PET) scan with the serotonin transporter radioligand, [(11)C]DASB. Depressed PD patients displayed a wide-spread increase (8-68%) in [(11)C]DASB specific binding outside of the striatum, which was significant in dorsolateral (37%) and prefrontal (68%) cortices. Elevated [(11)C]DASB binding was positively correlated with depressive symptoms but not with disease severity or duration. Compatible with recent PET/[(11)C]DASB findings in major depression, the present preliminary data suggest that increased [(11)C]DASB binding, possibly reflecting greater serotonin transporter density (up-regulation), might be a pathological feature of depression in Parkinson's disease-and possibly a characteristic of depressive illness in general.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aniline Compounds*
  • Case-Control Studies
  • Depression / diagnostic imaging*
  • Depression / etiology*
  • Depression / pathology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Parkinson Disease / complications*
  • Parkinson Disease / diagnostic imaging
  • Positron-Emission Tomography / methods*
  • Prefrontal Cortex / diagnostic imaging
  • Protein Binding / drug effects
  • Psychiatric Status Rating Scales
  • Serotonin Plasma Membrane Transport Proteins / metabolism*
  • Statistics, Nonparametric
  • Sulfides*


  • 3-amino-4-(2-dimethylaminomethylphenylsulfanyl)benzonitrile
  • Aniline Compounds
  • Serotonin Plasma Membrane Transport Proteins
  • Sulfides